Eli Lilly and Company and Merck extended an existing collaboration to evaluate the safety and efficacy of the combination of Lilly’s Alimta (pemetrexed for injection) and Merck’s Keytruda (pembrolizumab) in a phase III study in first-line nonsquamous non-small cell lung cancer. The study will be sponsored by Merck and will be open to patients with...
Urologic oncologist Wayne Brisbane thought his patient might be a good candidate for focal therapy.
